Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Dna X (SONM) Gross Profit (2018 - 2025)

Dna X's Gross Profit history spans 8 years, with the latest figure at $1.8 million for Q3 2025.

  • Quarterly results put Gross Profit at $1.8 million for Q3 2025, down 57.09% from a year ago — trailing twelve months through Sep 2025 was $10.8 million (down 28.83% YoY), and the annual figure for FY2024 was $9.9 million, down 48.66%.
  • Gross Profit for Q3 2025 was $1.8 million at Dna X, up from $845000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $8.4 million in Q1 2025 to a low of -$487000.0 in Q4 2021.
  • The 5-year median for Gross Profit is $2.9 million (2024), against an average of $3.1 million.
  • The sharpest move saw Gross Profit crashed 113.06% in 2021, then skyrocketed 907.39% in 2022.
  • Year by year, Gross Profit stood at -$487000.0 in 2021, then skyrocketed by 907.39% to $3.9 million in 2022, then skyrocketed by 30.21% to $5.1 million in 2023, then crashed by 103.57% to -$183000.0 in 2024, then skyrocketed by 1092.35% to $1.8 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $1.8 million, $845000.0, and $8.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.